Kidney Transplant; Complications Clinical Trial
Official title:
Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation
Avoiding warm ischemia time during vascular anastomosis of the renal allograft is important to prevent damage. The investigators are studying a cooling device that may control the temperature of the renal allograft during transplant surgery; attempting to keep temperatures at or below 5°C for at least 60 minutes. If found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys.
Warm ischemia can damage a renal allograft in many different ways often leading to early failure of the kidney transplant and sometimes even death of the transplant recipient. For this reason every effort is made to keep the allograft cold during the removal and transportation, and protocols have been developed to ensure this. Although kidneys are kept below 5°C during transportation, they re-warm rapidly during the transplant surgery. On average, kidneys are exposed to 40 or more minutes of dangerously warm temperatures during transplant surgery. To avoid damage, it is important to reduce the amount of time it is exposed to warm temperatures. Currently, there are no devices or standardized protocols available to ensure a kidney stays cold during the transplant surgery. The Principal Investigator has developed Kidney Skinn, a device that may control the temperature of the renal allograft during transplant surgery; keeping allograft temperatures at or below 5°C for at least 60 minutes. If found effective, this could eliminate warm ischemia and potentially prevent damage to transplanted kidneys. The device may also potentially provide retraction and support for the kidney during the transplant operation, making the surgery easier to perform. Additionally, the device may be found to be easily removed once the transplant is complete. A previous study was conducted with the Kidney Skinn in animals; the next step is to investigate whether the device can perform in the human clinical setting. This study will be done in 2 steps. Part A: a series of consecutive consenting patients to determine device initial safety, and Part B: a single-centre randomized-controlled pilot study of kidney transplant recipients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
Recruiting |
NCT06001320 -
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip
|
Early Phase 1 | |
Withdrawn |
NCT04560582 -
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
|
||
Not yet recruiting |
NCT05782543 -
Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion
|
N/A | |
Completed |
NCT03996551 -
ExeRTiOn2- The Weight Gain Prevention Exercise in Renal Transplant Online Study
|
N/A | |
Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
Recruiting |
NCT04508907 -
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06440330 -
Define Predictors for Posttransplant Diabetes Mellitus Study
|
||
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Recruiting |
NCT04713774 -
Bone Density and Vascular Calcifications Evolution After Renal Transplant
|
||
Active, not recruiting |
NCT05483725 -
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
|
||
Recruiting |
NCT06095492 -
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
|
N/A | |
Active, not recruiting |
NCT04207177 -
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
|
Phase 4 | |
Recruiting |
NCT03410654 -
Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.
|
Early Phase 1 | |
Completed |
NCT03373266 -
Serun Fluoride and Kidney Transplant
|
Phase 2 | |
Completed |
NCT04835948 -
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
|
||
Not yet recruiting |
NCT04514666 -
VOCs in Kidney and Liver Transplants
|
N/A | |
Recruiting |
NCT03373500 -
Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT05900401 -
Delayed Tolerance Through Mixed Chimerism
|
Phase 1/Phase 2 | |
Recruiting |
NCT05977387 -
Pediatric Kidney Transplant
|